Jpmorgan Chase & CO Passage Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Passage Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 273 shares of PASG stock, worth $191. This represents 0.0% of its overall portfolio holdings.
Number of Shares
273
Previous 273
-0.0%
Holding current value
$191
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PASG
# of Institutions
46Shares Held
32.7MCall Options Held
8.3KPut Options Held
400-
Orbimed Advisors LLC San Diego, CA10.1MShares$7.09 Million0.19% of portfolio
-
Vestal Point Capital, LP New York, NY6.05MShares$4.24 Million0.36% of portfolio
-
Versant Venture Management, LLC San Francisco, CA4.03MShares$2.82 Million7.06% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.75 Million2.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$1.45 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $38.1M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...